Figure 2.
Distinct families of cannabinergic ligands. (a) Endo‐ and phytocannabinoids; (b) cannabinoid receptors 1 and 2 (CB1/CB2) agonists; (c) cannabinoid agonists as pharmacological tools; (d) CB2 agonists; (e) CB1 antagonists; and (f) fatty acid amide hydrolase (FAAH) and AEA transport inhibitors.